Talquetamab

Talquetamab is an investigational bispecific antibody being studied for the treatment of multiple myeloma, a type of blood cancer that affects plasma cells in the bone marrow. Talquetamab is a bispecific antibody that targets both G protein-coupled receptor family C group 5 member D (GPRC5D) and CD3, a protein complex found on T cells. By binding to GPRC5D on multiple myeloma cells and CD3 on T cells, talquetamab redirects the T cells to attack and kill the cancerous plasma cells. Talquetamab is being investigated for the treatment of relapsed or refractory multiple myeloma, particularly in patients who have received multiple prior lines of therapy and have become resistant to existing treatments.

• Supplier: BOC Sciences
• Product #: 2226212-40-2
• Cas: 2226212-40-2